Tafluprost: a novel prostaglandin analog for treatment of glaucoma

Abstract

Since its introduction in 2008, initial studies have demonstrated that preserved and preservative-free tafluprost formulations have proven efficacy and safety in the treatment of glaucoma and ocular hypertension. Larger studies with longer follow-up are needed to assess long-term safety, efficacy, and tolerability compared with other prostaglandin analogs used for treating glaucoma.

Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension

“…It was first introduced in Japan in 2008 as a BAK containing multidose formulation, and in Germany in 2008 with approval for both a preserved and a PF tafluprost formulation 20 21. Currently, however, throughout the rest of the world, only the PF formulation is marketed 20 21. Initial reports in healthy eyes indicated that preserved tafluprost was at least as well tolerated and safe as preserved latanoprost when used over short periods 22–25.…”

The Role of Preservative-free Therapies in the Treatment of Glaucoma

“…19 Each of the prostaglandins has a different binding profile from the FP and EP receptors and as a result, has differing effects on blood vessels, blood flow and hyperaemia. [20][21][22] Consequently, individual patients show varying responses to the range of prostaglandins that are available and changing these drugs can have an effect on efficacy and/or tolerability.…”

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

“…Tafluprost is a prodrug in an ester form, which ensures ideal tissue penetration 7. About 75% of topically administered tafluprost can be absorbed by the rat cornea 8.…”

“…About 75% of topically administered tafluprost can be absorbed by the rat cornea 8. When tafluprost enters the cornea, it is hydrolyzed by corneal esterases to the active acid form and is soluble in the aqueous humor 7. Compared with other prostaglandin analogs, the major modification of tafluprost is the substitution of the C-15 hydroxyl group with two fluorine atoms 6.…”

“…Compared with other prostaglandin analogs, the major modification of tafluprost is the substitution of the C-15 hydroxyl group with two fluorine atoms 6. This modification renders tafluprost resistant to 15-hydroxydehydrogenase 7. Therefore, tafluprost is only metabolized by beta-oxidation and subsequent oxidation 9,10.…”